7 Best Peptides for Weight Loss

What to Know Before Choosing a Peptide for Weight Loss

The weight loss peptide landscape is unusually wide. At one end sit prescription medications with Phase 3 clinical trial data, FDA approval, and years of real-world use behind them. At the other end sit growth hormone peptides, fat-fragment analogs, and support compounds that circulate in wellness clinics, anti-aging protocols, and community forums, sometimes with very little published human evidence. Both categories belong in an honest guide, because people are using compounds from across that entire spectrum.

A compound earns a spot on this list because people are using it for weight loss, or are actively discussing using it. That test does not require FDA approval, and it does not require a randomized controlled trial. FDA-approved medications, telemedicine-prescribed compounds, and research-only peptides are all eligible. What evidence exists for each is stated plainly inside its entry: a compound with Phase 3 trial data gets that described in full, and a compound whose backing is primarily experiential gets that stated just as clearly. Evidence strength shapes how a compound is described, never whether it appears.

The entries below are numbered by how prominently each compound shows up in research and real-world use, not as a ranking of one being better than another for any individual. The right choice depends on your health history, your specific weight loss goals, what other compounds or medications you are using, and what a qualified clinician or the MyPeptidePal app helps you work out from there.

1. Tirzepatide: The Highest-Efficacy Approved Option

Tirzepatide is a dual agonist that activates both the GLP-1 receptor and the GIP receptor. GLP-1, glucagon-like peptide-1, and GIP, glucose-dependent insulinotropic polypeptide, are two gut hormones that play central roles in appetite regulation, insulin release, and metabolic signaling. Think of these receptors as two separate volume knobs on your body's fullness and blood sugar control systems. Tirzepatide turns both up at the same time, which appears to explain why it consistently outperforms compounds that activate only one.

In Phase 3 clinical trials, participants taking tirzepatide at the highest approved dose lost an average of up to 21 percent of their body weight over 72 weeks, roughly 16 and a half months. Those results were achieved alongside calorie restriction and exercise, which is an important context for every compound on this list. The dose-response was clear and consistent enough that it earned FDA approval for chronic weight management under the brand name Zepbound.

The mechanism that separates tirzepatide from GLP-1-only agents is the GIP component. GLP-1 activation on its own suppresses appetite and slows how quickly food moves from the stomach to the intestines, prolonging the sensation of fullness and reducing the speed at which carbohydrates are absorbed. Adding GIP activation appears to enhance insulin sensitivity and may promote what researchers call fat browning, the conversion of white fat tissue from energy storage mode into energy burning. The combination of these effects across two separate hormone pathways appears to drive the roughly six percentage point efficacy advantage tirzepatide holds over semaglutide.

Tirzepatide is prescribed through licensed clinicians and telemedicine platforms. The side effect profile is consistent with the GLP-1 class: nausea, vomiting, diarrhea, and constipation are most common and tend to cluster during the early dose-escalation phase. More serious risks include pancreatitis, gallbladder complications, and a black box warning for thyroid tumors observed in rodent studies, though the human significance of the thyroid finding is not yet established. People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use tirzepatide.

2. Semaglutide: The Most Widely Used GLP-1 Agonist

Semaglutide is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1 in the body. Its mechanism focuses on three interlocking effects: appetite suppression through signals in the hypothalamus, the brain region that governs hunger and energy balance; delayed gastric emptying, which slows how quickly food leaves the stomach and extends the window of feeling full; and reduced glucagon output from the pancreas, which keeps blood sugar more stable and cuts one of the signals that drives overeating.

In Phase 3 clinical trials, semaglutide at its highest approved dose produced average weight loss of roughly 15 percent of body weight over 68 weeks, again alongside lifestyle intervention. The injectable form carries the brand name Wegovy for weight management and Ozempic for type 2 diabetes, with Ozempic widely prescribed off-label for weight loss. An oral tablet version called Rybelsus is also FDA-approved for weight loss.

Semaglutide is the most widely used peptide in this category by volume and community discussion. Its off-patent status in some markets has improved access, and the breadth of real-world experience with it is substantial. Users report outcomes that generally track the trial data, though individual results vary meaningfully. Some users have raised concerns about lean muscle mass loss during rapid weight reduction, a pattern that appears across the GLP-1 class and reinforces the value of pairing these compounds with resistance training.

The side effect profile mirrors the class: primarily gastrointestinal symptoms during dose escalation, with the same serious-risk profile as tirzepatide, including pancreatitis, gallbladder disease, kidney complications, and the black box thyroid warning. Both injectable and oral semaglutide are available through licensed prescription and telemedicine providers.

3. Retatrutide: The Pipeline Triple Agonist

Retatrutide adds a third receptor to the dual-agonist model. Where tirzepatide activates GLP-1 and GIP, retatrutide activates all three: GLP-1, GIP, and the glucagon receptor. Glucagon is a hormone that tells the liver to release stored sugar and raises energy expenditure. Adding glucagon receptor activation to the GLP-1 and GIP signals appears to push total energy expenditure meaningfully higher than what either approved agent achieves.

Phase 2 trial data showed average weight loss of approximately 30 percent of body weight over 80 weeks, with more than 45 percent of participants losing more than 30 percent of their starting weight. Every participant receiving the higher tested doses lost at least 5 percent of body weight. A separate dataset reported up to 28.7 percent weight loss over 68 weeks. Those are the most striking efficacy numbers published for any weight loss compound to date, and they have driven significant interest in community discussions.

Retatrutide is not FDA-approved as of mid-2026. Phase 3 trials were expected to complete in the first half of 2026, and peer-reviewed Phase 3 data has not yet been published. The Phase 2 results are compelling but belong to a different standard of evidence than the approved agents above. A portion of community discussion about retatrutide concerns compounded or unregulated online versions, which the FDA has specifically warned carry unknown safety profiles, dosing risks, and purity concerns. The Phase 2 data justifies its place near the top of this list in terms of studied potential; the regulatory status means the path to using it through verified channels is not yet fully established.

4. Liraglutide: The First-in-Class GLP-1 Option

Liraglutide was the first GLP-1 receptor agonist to receive FDA approval specifically for weight loss, under the brand name Saxenda, before either semaglutide or tirzepatide entered the market. Its mechanism is the same GLP-1 pathway: appetite suppression through hypothalamic signaling, delayed gastric emptying, and glucagon inhibition for blood sugar stability.

In Phase 3 trials, liraglutide produced average weight loss of approximately 8 percent of body weight over 56 weeks at the highest dose. That is a meaningful result, but it is notably lower than what semaglutide and tirzepatide achieved in their respective trials, which is the primary reason it holds a fourth position in most current analyses despite being first to market.

Liraglutide is still prescribed through licensed clinicians and carries FDA approval for chronic weight management in adults. Research has shown that combining liraglutide with regular structured exercise produces significantly better long-term outcomes and helps reduce the weight regain that tends to occur when GLP-1 medications are discontinued. Its established safety record over more than a decade of clinical use distinguishes it from newer agents, which carry more unknowns simply because they have been used in broader populations for a shorter time. The side effect profile follows the class pattern, primarily gastrointestinal during dose escalation, with the same serious-risk considerations including the black box thyroid tumor warning.

5. Tesamorelin: For Visceral Fat Specifically

Tesamorelin works through a completely different pathway than the GLP-1 agonists. It is a synthetic analog of growth hormone-releasing hormone, the signal the hypothalamus sends to tell the pituitary gland to release growth hormone. Rather than acting directly on appetite or gut signaling, tesamorelin stimulates the body's own natural growth hormone pulse, which in turn affects fat metabolism and body composition.

The compound is FDA-approved, but only for a specific indication: HIV-associated lipodystrophy, a condition in which people on certain antiretroviral therapies accumulate excess visceral fat, the deep abdominal fat that surrounds the organs. In clinical trials for that condition, tesamorelin reduced visceral fat by roughly 15 to 20 percent. That fat-reduction signal is what has led to its off-label use in physician-supervised wellness and anti-aging contexts among people without HIV who are specifically targeting abdominal fat rather than overall body weight.

The honest framing for its place on this list: tesamorelin does not have published human trial data supporting its use as a general weight loss agent. What it has is FDA approval for a related and specific fat-reduction indication, a plausible mechanism, and real-world off-label use through physician-supervised anti-aging clinics. It is extrapolated from the HIV-associated indication to general visceral fat reduction, which is a narrower and more specific goal than the overall weight loss the GLP-1 agonists address. It is available through telemedicine providers who prescribe it off-label.

6. CJC-1295 and Ipamorelin: For Muscle Preservation During Weight Loss

CJC-1295 and Ipamorelin are almost always discussed and used together in practice, so treating them as a pair reflects how they actually appear in the literature and community protocols. CJC-1295 is a synthetic analog of growth hormone-releasing hormone. Ipamorelin is a growth hormone-releasing peptide that acts on a separate receptor to also stimulate growth hormone release. Used together, they produce a more sustained elevation of natural growth hormone than either achieves alone.

Neither compound is FDA-approved for weight loss or fat reduction. Their role in weight loss discussions is specifically as a complement to the GLP-1 agonists rather than a replacement, addressing the muscle mass concern. Rapid weight loss through GLP-1 therapy can include loss of lean muscle alongside fat, which raises body fat percentage even as the scale number falls. Growth hormone promotes muscle protein synthesis and supports lean tissue preservation, and that is the mechanism behind pairing this stack with a primary fat loss agent.

The evidence base for this combination in the weight loss context is primarily drawn from animal models and wellness clinic case reporting rather than controlled human trials. No large randomized controlled trial has evaluated CJC-1295 plus Ipamorelin specifically for lean mass preservation during GLP-1 therapy in the general population as of 2026. What exists is a plausible mechanism, real-world use in anti-aging and wellness settings, and a consistent pattern of community-reported use among people running GLP-1 protocols who want to protect lean mass. Both compounds are available through compounding pharmacies and research chemical channels, and neither carries the FDA safety review that the approved GLP-1 agents have.

7. AOD-9604: The Fat-Fragment Analog

AOD-9604 is a synthetic fragment of human growth hormone, specifically the portion of the HGH molecule that researchers identified as responsible for fat metabolism rather than the growth-promoting effects associated with the full molecule. The theoretical appeal is direct: isolate the fat-burning signal from HGH and remove the insulin-affecting and tissue-growth signals, and you have a compound that targets fat breakdown more selectively.

In practice, the human evidence base for AOD-9604 is limited. Clinical trials were conducted in the early 2000s with mixed results, and it has never received FDA approval for any indication. The available human data does not establish the consistent fat-loss efficacy that the theoretical mechanism might suggest. Most current weight loss literature treats AOD-9604 as a legacy compound, one that helped establish the concept of HGH fragment peptides but has been largely displaced by the GLP-1 class in terms of real-world interest and clinical backing.

It continues to appear in community discussions about peptides for fat loss, particularly among people researching non-GLP-1 options or exploring growth hormone peptide combinations. Community-reported use is real and ongoing, which is what keeps it on this list. The evidence here is experiential rather than clinical, and the compounds above it offer substantially better-established efficacy data for the goal of weight loss.

How These Peptides Compare

Frequently Asked Questions

Are Peptides for Weight Loss Legal to Use in the United States?

The answer depends entirely on which compound you are asking about. Tirzepatide, semaglutide, and liraglutide are FDA-approved prescription medications and are fully legal when prescribed by a licensed clinician or through a telemedicine provider. Tesamorelin is FDA-approved for its specific indication and legally prescribed off-label by physicians. CJC-1295, Ipamorelin, and AOD-9604 are not FDA-approved for weight loss and occupy a more complex regulatory space, commonly available through compounding pharmacies or research chemical channels without the oversight that an approved drug carries. The FDA has issued formal warnings about unapproved GLP-1 compounds sold online that are advertised for research use but shipped with human dosing instructions.

How Long Does It Take to See Results with Weight Loss Peptides?

For the FDA-approved GLP-1 agonists, the clinical trials measured outcomes over 56 to 72 weeks, and those timelines reflect what it takes to achieve the headline weight loss percentages. In practice, users commonly report noticing appetite suppression within the first week or two, with measurable weight change becoming more apparent over the following months alongside dietary adjustments. For the growth hormone peptides and off-label compounds, no standardized clinical timeline has been established in controlled research, and the evidence for how quickly any change occurs is drawn from user-reported experience rather than measured trial outcomes.

Do You Need a Prescription to Access These Peptides?

The FDA-approved compounds on this list, tirzepatide, semaglutide, and liraglutide, require a valid prescription from a licensed clinician and are not legally available through any other channel in the United States. Tesamorelin also requires a prescription. The remaining compounds, CJC-1295, Ipamorelin, and AOD-9604, are not approved prescription drugs for weight loss, but accessing them through compounding pharmacies typically involves a clinician's order, while research chemical channels operate outside that structure entirely and without regulatory oversight. The distinction matters because compounds without FDA review have not been evaluated for safety, purity, or consistent dosing at the population level.

Will You Regain Weight After Stopping These Peptides?

Weight regain after stopping GLP-1 medications is a well-established pattern in clinical data. Discontinuing semaglutide or tirzepatide without maintaining the lifestyle changes that supported weight loss during treatment tends to result in significant regain over the following months. Research has shown that combining liraglutide with structured exercise reduces regain compared to medication use alone, suggesting that the behavioral habits built during treatment are the most durable component of long-term results. These compounds are tools for shifting appetite signals and metabolic environment; they work best when paired with the dietary and activity patterns you intend to sustain beyond the treatment period.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for weight loss in one place.